Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 22:13:1032314.
doi: 10.3389/fimmu.2022.1032314. eCollection 2022.

Predictive biomarkers of colon cancer immunotherapy: Present and future

Wanting Hou  1 , Cheng Yi  1 , Hong Zhu  1
Affiliations
Review

Predictive biomarkers of colon cancer immunotherapy: Present and future

Wanting Hou et al. Front Immunol. .

Abstract

Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors (ICIs) have shown clinical benefits for colon cancer patients, especially those with high microsatellite instability (MSI-H). In 2020, the US Food and Drug Administration (FDA)-approved ICI pembrolizumab as the first-line treatment for metastatic MSI-H colon cancer patients. Additionally, neoadjuvant immunotherapy has presented efficacy in treating early-stage colon cancer patients. Although MSI has been thought of as an effective predictive biomarker for colon cancer immunotherapy, only a small proportion of colon cancer patients were MSI-H, and certain colon cancer patients with MSI-H presented intrinsic or acquired resistance to immunotherapy. Thus, further search for predictive biomarkers to stratify patients is meaningful in colon cancer immunotherapy. Except for MSI, other biomarkers, such as PD-L1 expression level, tumor mutation burden (TMB), tumor-infiltrating lymphocytes (TILs), certain gut microbiota, ctDNA, and circulating immune cells were also proposed to be correlated with patient survival and ICI efficacy in some colon cancer clinical studies. Moreover, developing new diagnostic techniques helps identify accurate predictive biomarkers for colon cancer immunotherapy. In this review, we outline the reported predictive biomarkers in colon cancer immunotherapy and further discuss the prospects of technological changes for biomarker development in colon cancer immunotherapy.

Keywords: biomarker; colon cancer; immune checkpoint inhibitor (ICI); immunotherapy; predictive.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Predictive biomarkers of colon cancer immunotherapy MSI, microsatellite instability; TMB, total mutation burden; POLE:/POLD1, DNA polymerase ϵ (POLE) and δ (POLD1); TILs, tumor-infiltrating lymphocytes; PD-L1, programmed cell death-ligand 1; TLS, tertiary lymphoid structure; CAF, cancer-associated fibroblast; ctDNA, circulating tumor DNA; bTMB, blood total mutation burden; NLR, neutrophil-lymphocyte ratio.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: Cancer J Clin (2022) 72(1):7–33. doi: 10.3322/caac.21708 - DOI - PubMed
    1. Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol Off J Am Soc Clin Oncol (2015) 33(16):1787–96. doi: 10.1200/JCO.2014.60.0213 - DOI - PubMed
    1. Wu C. Systemic therapy for colon cancer. Surg Oncol Clinics North America. (2018) 27(2):235–42. doi: 10.1016/j.soc.2017.11.001 - DOI - PubMed
    1. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-Instability-High advanced colorectal cancer. New Engl J Med (2020) 383(23):2207–18. doi: 10.1056/NEJMoa2017699 - DOI - PubMed
    1. Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-High/Mismatch repair-deficient metastatic colorectal cancer: The phase II CheckMate 142 study. J Clin Oncol (2022) 40(2):161–70. doi: 10.1200/JCO.21.01015 - DOI - PubMed

Publication types